

bodaustralia

BEAUTIFUL SCIENCE

APRIL 2017 – CANNABIS EXTRACT LOI WITH LINNEA NATURAL PHARMA SOLUTIONS

ASX:BDA



01
INTRO

- Medicinal cannabis is undergoing a resurgence, recent legal & regulatory changes have seen great interest in the application of this ancient herb into mainstream medical practice in Australia
- A growing number of clinical studies indicate that cannabis & its phytocannabinoids have a relevant medicinal value in the treatment of certain conditions
- The discovery of the endocannabinoids system & its physiological functions contribute to understanding the significant potential role cannabis can play in medicine
- Finding a standardised, consistent, reproducible product for the market will have significant potential benefits to those businesses involved



02 LOI Linnea & BOD

- Bod has executed a binding letter of intent (LOI) with Swiss manufacturer of botanical extracts & pharmaceutical ingredients, Linnea Natural Pharma Solutions
- Bod to develop products using Linnea's unique & standardised low-THC cannabis extracts
- Bod to import raw materials, manufacture products plus coordinate & implement relevant clinical trials
- Bod to establish pharmaceutical advisory team to oversee the development of clinical trials
- Importation and manufacturing subject to regulatory and licence approvals



03 why linnea? differentiating factors



- Established producer of high quality medicinal cannabis products (as well a range of other standardised herbal products)
- Experience in the production & export of numerous herbal products via GMP manufacturer
- Seed to patient production via Vitaplant (Romanshorn, Switzerland)
- Standardised extract made from the flowering tops of the female cannabis sativa plant available in oil, water & powdered forms in concentrations from 0.5-20%
- High CBD, very low THC (<0.1%)

04 IMPORTANCE OF SOURCING

- Plants are cultivated in greenhouses or in fields, in accordance with strict procedures that guarantee
 GMP application & compliance with national regulations
- Plants are specifically bred to strict characteristics
- Extracts are developed from only the flowering tops of the female cannabis sativa plant




05 LINNEA'S EXTRACTION PROCESS IS UNIQUE



- The Linnea extract is obtained by a proprietary solvent extraction performed to maximize the concentration of CBD (Cannabidiol) content from the plant
- The extraction process ensures the natural profile of the cannabis is maintained
- Linnea the first Swiss company to produce a GMP cannabis extract

Linnea's extracts guarantee the natural phytocomplex of cannabis

06 LINNEA PROCESSING



Linnea cannabis extracts are manufactured under GMP & controlled, validated analytical methods



DTOCANNABINOIDS Indications for use

CBD (cannabidiol) is one of the major non-psychotropic cannabinoids of cannabis. Potential therapeutic uses:

- Anti-Inflammatory
- Nausea and Vomiting
- Muscle relaxation
- Neuroprotection
- Anxiety disorders
- Allergy and asthma
- Sleep disorders
- Skin disease

O8 TWO STREAMS OF COMMERCIALISATION



Topical use (skincare)



The Linnea relationship offers Bod two streams to commercial success

O9 EXPANDING ACROSS BOTH BOD'S BUSINESS UNITS

SKINCARE

Dr Roebucks

- Skincare range with natural & active ingredients, unique & evidence based 30 year old family formula
- Bod is exclusive distributor Australia, NZ & Asia

BIOEFFECT

- Premium, innovative skin care brand born in Iceland, based on ten years research & developed by bio-scientists – offers a unique efficacy & purity
- Bod exclusive distributor Australia, & NZ

Pommade Divine

- Multipurpose balm that is a natural alternative to Lucas Paw Paw
- Bod exclusive distributor Australia, NZ & Asia

NATURAL REMEDIES

Pinpoint

- Natural remedy for memory & improved concentration, based on the extract Bacopa Monnieri
- Comes under Bod Australia brand

Flexofytol

- Natural anti-inflammatory targeting arthritis, joint pain, brain health
- Turmeric-based product licensed from Belgian herbal medicine leader Tilman S.A marketed under the Bod Australia brand

New LOI with Linnea allows Bod to expand its product offerings across both business units, utilising a unique & standardised cannabis extract

10 NIOSKIN™ MEDCAN An innovative concentrate – phytoactives from cannabis for topical use

Cannabis phytocomplex has a role in the control of epidermal physiology & skin differentiation genes, anti-inflammatory & immunological related skin disorders, neurodermitis, contact eczema, hitching dermatosis, rosacea. Indications include:

- Anti-inflammatory
- Dermatosis
- Contact dermatosis
- Immunological related skin disorders

11 NIOSKIN ADVANTAGES Cosmetic formulation

- Easy to formulate by introduction in the water or lipid phase of emulsion
- Direct use in cold phase
- Self-preservative
- Soluble in water and dispersible in lipid
- Stable at a wide range of PH
- Solvent free



12 NIOSKIN APPLICATIONS

Applications to be explored include face & body solutions based on:

- Serums & day base creams
- Facial mask
- Beauty water
- Hand cream
- Eye care serum
- BB creams





13 THERAPEUTIC


- Product(s) will focus on areas such as but not limited nausea and vomiting, anti-inflammation, neuroprotection and anxiety disorders
- Clinical trials to be implemented to establish relevant indications for use (trial design, ethics, data collection)
- Investigation of novel delivery system (wafer/transdermal patch)
- Relevant regulatory restrictions & authorities to be satisfied (import permission)

14 MEDICINAL CANNABIS MARKET

- Common diseases for which cannabinoids have shown high levels of efficacy have combined sales of more than US\$500 million to date¹
- Cannabinoids are legal in 23 U.S states and the medical cannabis market is estimated to be worth over US\$20 billion in 2018²
- Phytocannabinoids have potential in some of the largest therapeutic markets in the world with the global antiinflammatory therapeutics market expected to exceed US\$100 billion by 2020³ and the global anxiety disorders market to reach US\$18.3 billion by 2025⁴.
- Global nutraceuticals market expected to reach US\$204.8 billion in 2017⁵
- Clear regulatory pathway developing in Australia rapid growth expected

¹ArcView Group, University of Sydney ²Luxury and cosmetic The EY Financial Factbook2013 ed ition, The HIA, Statista ³ Allied Market Research ² ⁴ Grand View Research ⁵ Transparency Market Research (NY, USA)

15 COMPETITIVE ANALYSIS



	AusCann Group (AC8)	Medlab Clinical (MDC)	MMJ Phytotech (MMJ)	MGC Pharmaceuticals (MXC)	Creso Pharma Ltd (CPH)	Zelda Therapeutics (ZLD)	Bod Australia (BDA)
Mkt Cap (Fully Diluted)	\$219.5m	\$176.4m	\$166.4m	\$91.5m	\$64.2m	\$64.2m	\$14.4m
High level ddescription	Produces and provides clinically validated cannabis medicines with THC and CBD extracts.	Cannabis-based medicine (1 :1 ratio of CBD and THC) for oncology patients with intractable pain, utilising its small particle medicine delivery system, Nanocelle.	Cannabis producer, targeting medical and recreational markets.	Develops and supplies of non-psychoactive cannabidiol (CBD) resin extract for the cosmetics and medical markets.	Develops cannabis and hemp-derived therapeutic- grade cannabidiol nutraceuticals (food supplements) and medical cannabis products – high CBD extract.	Researches into the use of medical cannabis to treat a variety of ailments.	Develops skincare and therapeutic (medical) products using Linnea's unique and standardised low-THC/ high- CBD cannabis extracts. High CBD, very low THC
Source of extract	Partnered with DayaCann, a licensed medical cannabis grower in Chile.	Import from Aphria Inc, a licensed producer based in Canada.	Cultivation subsidiary located in Canada as well as Israeli production and clinical research.	Growing operations in Czech Republic and Slovenian outdoor crops to be planted by late April/May 2017.	Established cannabis growing operations on certified organic farms in Slovakia.	Manufacturing agreement in place with AusCann,	Swiss manufacturer of botanical extracts & pharmaceutical ingredient, Linnea Natural Pharma Solutions.



16 UPDATE ON BOD'S BUSINESS STRATEGY

STRATEGY

Build distribution channels

- Pharmacy channel focus opportunity to leverage into other distribution channels
- Pursuing additional channels inc travel, spa, e-commerce markets
- · International expansion underway ahead of schedule

Grow sales of existing portfolio of products

- Dr Roebucks & BIOEFFECT sales building in stores inc David Jones, Sephora
- Bod branded products Pinpoint & Flexfytol pre-ordered, sales in March
- Natural products with quality edge on competing brands

Add new & complementary product lines

- Identifying & developing natural medicine opportunities
- Adding complementary, high quality skin care brands to portfolio
- Moving into additional verticals

UPDATE

- Attendance at pharmacy conference
- Continuing sales meetings with Australia's largest pharmacy banner groups
- Dr Roebucks launch new everyday range packaging
- Bod branded products Pinpoint & Flexfytol sales commencing this month

Distribution deal signed with Pommade Divine

LOI signed with Linnea

17 ABOUT BOD

Focused on delivering natural, evidence based solutions for the body – Inside & Out

Brands positioned across skin care, baby skin care, brain health, anti-inflammatory, & immune support segments

Develops, manufactures, markets, imports & exports products across Australia & Asia

Commencing rapid growth phase

- Aggressively building distribution channels with a focus on pharmacy in Australia
- Expanding to export markets with initial focus on China
- New & complementary products launching in the March & June quarters
- Leveraging relationships & expertise to commercialise products utilising a unique & standardised cannabis extract



18 Corporate

- Bod listed on the ASX on 27 October 2016 after raising A\$6 million in its Initial Public Offering (IPO), issuing 30m shares at A\$0.20 with indicative market capitalisation upon listing of A\$9.1m
- Company achieved cash receipts of
 \$233,000 to 31 December 2016, which
 is 232% growth on full year FY16
 (\$140,442) on an annualised basis
- Cash balance of \$4.45 million at 31 December 2016

46.0 million
\$0.28
12.9 million
\$0.17-\$0.35

Approximately 9.5m options on issue

Shareholders	Shares (m)
Jo Patterson	5.7
Noir Ted Pty Ltd (Craig Weller)	5.0
JP Morgan Nominees	3.7
UBS Nominees	1.8
Citicorp Nominees	1.5



bodaustralia

CONTACT

JO PATTERSON BOD AUSTRALIA +61 2 9199 5018

INVESTOR RELATIONS MATT WRIGHT MATT@NWRCOMMUNICATIONS.COM.AU +61 451 896 420

